摘要
目的:探讨联合检测血清CA125、CA153和CEA水平对卵巢癌的的诊断价值。方法:对66例卵巢癌患者、86例卵巢良性肿瘤患者及对照组100名健康妇女,应用化学发光免疫法测定血清CA125、CA153和CEA水平,然后进行统计学分析。结果:卵巢癌组与正常对照组比较,卵巢癌组CA125、CA153和CEA水平及阳性率明显升高,三项标志物的阳性率分别为72.7%、62.1%和34.8%,三项联合检测的阳性率为89.4%。结论:血清CA125、CA153和CEA联检可以提高卵巢癌早期诊断的阳性率,对卵巢肿瘤的良恶性辅助诊断及鉴别诊断具有一定应用价值。
Objective：To explore the clinical values of combined detection of serum CA125,CA153 and CEA levels in the early diagnosis of ovarian cancer.Methods：The serum CA125,CA153 and CEA levels in 66 patients with ovarian cancer,86 patients with benign ovarian tumor and 100 healthy women controls were measured by Chemical Iuminescence Immunoassay.Results：The results showed that serum CA125,CA153 and CEA levels and positive rate in patients with ovarian cancer were significantly higher that of in patients with benign ovarian tumor and healthy controls.The positive rates of CA125,CA153 and CEA in patients with ovarian cancer were 72.7%,62.1% and 34.8%,respectively.The positive rate of three markers combined detection was 89.4%.Conclusions：The combined detection of the three markers may increase the positive rate in the early diagnosis of ovarian cancer,and help to differentiate the benign and malignant ovarian tumor.
